To include your compound in the COVID-19 Resource Center, submit it here.

Bellicum announces trial holds for switch T cell candidates

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said FDA placed a clinical hold on U.S. trials of the company's adjunct, safety switch-containing T cell therapy BPX-501 in patients receiving partial match hematopoietic stem cell transplants (HSCTs). According to the

Read the full 368 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE